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High-fat diets (HFD) are linked to obesity and associated comorbidities and induce
pathogenic T helper (Th) 17 cells while decreasing regulatory T cells (Treg). This pro-
inflammatory environment also aggravates immunopathology in experimental
autoimmune encephalomyelitis (EAE) as a prototype model of T cell mediated
autoimmunity. The strong association of HFD to obesity as well as the increasing risk of
autoimmunity in the Western world stresses the importance to identify compounds that
counteract this metabolically induced pro-inflammatory state in humans. One prominent
candidate is the short-chain fatty acid propionate (PA) that was recently identified as
potent therapy in the autoimmune disease multiple sclerosis by enhancing Treg cell
frequencies and functionality. Mice were fed a HFD rich lauric acid (LA) and treated either
with water or PA during MOG35-55-EAE. We analyzed Treg and Th17 cell frequencies in
different tissues, antigen-specific cell proliferation and cytokine secretion, investigated
Treg cell functionality by suppression assays and IL-10 signaling blockade and employed
Western blotting to investigate the involvement of p38-MAPK signaling. Finally, we
performed an explorative study in obese and non-obese MS patients, investigating
fecal PA concentrations as well as peripheral Th17 and Treg frequencies before and
after 90 days of daily PA intake. As compared to controls, mice on a HFD displayed amore
severe course of EAE with enhanced demyelination and immune cell infiltration in the
spinal cord. PA treatment prevented this disease enhancing effect of HFD by inhibiting
Th17 mediated inflammatory processes in the gut and the spleen. Blocking experiments
and signaling studies revealed p38-MAPK and IL-10 signaling as important targets linking
the beneficial effects of PA treatment and reduced inflammation due to enhanced Treg
frequency and functionality. An explorative study in a small group of MS patients revealed
reduced PA concentrations in fecal samples of obese MS patients compared to the non-
obese group, coinciding with increased Th17 but decreased Treg cells in obese patients.org June 2021 | Volume 12 | Article 7016261
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Frontiers in Immunology | www.frontiersin.Importantly, PA intake could restore the Treg-Th17 homeostasis. Our data thus identify
Th17 responses as an important target for the beneficial effects of PA in HFD and obesity
in addition to the recently identified potential of PA as a Treg inducing therapy in T cell
mediated autoimmunity.Keywords: high-fat diet, EAE, propionic acid, immunosuppression, multiple sclerosisINTRODUCTION
An excess consumption of a so called ‘Western Diet’ has been
linked to obesity, a long discussed risk factor for diabetes (1),
hypertension (2), and arthritis (3). Moreover, observational
studies demonstrated that obesity during young adulthood is
associated with a higher risk of developing multiple sclerosis (4,
5), a T cell mediated neuroinflammatory disease. First murine
studies showed that diet-induced obesity may impact regulatory
T cells (Treg) and particularly promote T helper (Th) 17 driven
immunity (6, 7), both cell types contributing to MS
immunopathology. Later, we demonstrated that saturated long-
chain fatty acids (LCFA) as integral components of the ‘Western
Diet’ may link diet-induced obesity and multiple sclerosis risk
(8). In the murine model of multiple sclerosis, experimental
autoimmune encephalomyelitis (EAE), mice fed a LCFA-rich
diet displayed a more severe disease course with an increased
number of pro-inflammatory Th17 cells in the gut, the spleen
and the spinal cord, while Treg numbers were decreased (8). This
LCFA induced shift towards a pro-inflammatory environment
may not only be relevant for EAE and multiple sclerosis, but also
other diseases involving a T cell-mediated immunopathology
such as rheumatoid arthritis, hypertension, atherosclerosis,
psoriasis or inflammatory bowel disease (9–14). Moreover, the
high prevalence of obesity and the number of related
comorbidities makes it highly important to identify substances
that counteract high-fat induced inflammation in T cell mediated
diseases. As such, short-chain fatty acids (SCFA) may be of
potential importance. SCFA such as acetate, butyrate or
propionate (PA) are the main intestinal metabolites derived
from gut microbiota processed dietary fiber. These compounds
may regulate differentiation, activation and recruitment of
immune cells. Besides local effects in the gut, SCFA may also
harbor immunomodulatory capacities . Recently, we
demonstrated that PA treatment decreases Th17 cell
differentiation (8), while it increases Treg cells and enhances
their suppressive capacity (8, 15, 16). The induction of an anti-
inflammatory phenotype by SCFA treatment ameliorated clinical
signs in EAE diseased mice with increased Treg numbers in the
gut and spleen (8). These data from animal studies were
transferred to humans where SCFA efficiently counteracted the
progression of inflammatory diseases. Supplementation of PA to
therapy-naive multiple sclerosis patients and as an add-on to
multiple sclerosis immunotherapy significantly increased
functionally competent Treg cells leading to reduced annual
relapse rates together with reduced brain atrophy and a
stabilization of disability (16). Another study in rheumatoid
arthritis patients identified that high-fiber intake increasedorg 2circulating Treg cells paralleled by improved disease-outcome
(17), s trengthening the potentia l of dietary SCFA
supplementation to beneficially modulate immune-mediated
diseases by the induction of Treg cells. We here used EAE as a
prototype model of T cell immunopathology to investigate
whether SCFA may counteract the high-fat diet-induced
increase of Th17 cells by enhancing Treg cell responses,
thereby preventing disease progression. These data could be
translated to a small cohort of multiple sclerosis patients,
indicating the importance for human diseases.MATERIAL AND METHODS
Animal Experiments and Diet
All animal experiments were in accordance with the German
laws for animal protection and were approved by the local ethic
committees (Erlangen AZ 55.2 DMS-2532-2-27). C57Bl/6 mice
(male and female) were housed in the animal care facility of the
Friedrich-Alexander University Erlangen under a 12-h day-night
cycle and standardized environmental conditions. Mice were fed
control chow (ssniff EF R/M Control E15000-04, 4.2 % crude fat)
or chow rich in the medium chain fatty acid lauric acid (LA;
ssniff EF R/M E15116-34; 30.9 % crude fat) 4 weeks before EAE
induction and had ad libitum access to food and water
throughout the adaption and observation period. LA+PA mice
received 150 mM propionic acid (PA) via oral gavage starting
from the day of immunization in addition to LA-rich chow.
Control and LA mice received water via oral gavage.
EAE Induction
10-12 week-old mice were anaesthetized and subcutaneously
injected with 200 µg myelin oligodendrocyte glycoprotein
(MOG35-55) and 200 µg Complete Freund’s Adjuvant (CFA),
containing 4 mg/ml Mycobacterium tuberculosis (H37RA). Mice
received 200 ng pertussis toxin intraperitoneally on the day of
immunization and two days later. Clinical scoring was
performed on a 10-point scale (18).
Histological Analysis
Mice were perfused with 4 % PFA on day 21 of EAE and spinal
cord tissue was embedded in paraffin after 3 h post-fixation in
4 % PFA. 4 µm cross sections were deparaffinized in xylene and
rehydrated in decreasing concentrations of ethanol before
antigen retrieval in 1mM EDTA or citrate buffer. Antigens
were blocked with 10 % BSA/PBS before incubation with the
primary antibody over night at 4°C. Biotinylated secondary
antibodies were applied for 60 min at room temperatureJune 2021 | Volume 12 | Article 701626
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Vector Laboratories, Inc. Burlingame, CA). Reactivity was
visualized with diamino-3,3 ’benzidine (DAB, Vector
Laboratories, Inc. Burlingame, CA). Slides were counterstained
using Mayer´s hemalaun solution (Merck, Darmstadt,
Germany). The following antibodies were used: anti-CD3 (rat,
1:200, Biolegend), anti-Mac-3 (rat, 1:200, BD Biosciences), anti-
GFAP (rabbit, 1:1000, Dako), anti-rabbit IgG (H+L) (goat, 1:200,
Vector Laboratories), anti-rat IgG (H+L) (rabbit, 1:200, Vector
Laboratories). Demyelination was assessed by luxol fast blue-
periodic acid Schiff (LFB-PAS) staining. In brief, spinal cord
cross sections were rehydrated in xylene and 96 % ethanol and
incubated overnight in 0.1% LFB solution at 56°C. Sections were
washed in 70% ethanol, incubated in 1% Li2CO3 for few seconds
and transferred into 0.8% periodic acid solution for 10 min.
Sections were stained in Schiff’s reagent for 20 min and washed
in sulfite solution followed by further washing in A.dest.,
dehydrating and mounting. Axonal density was investigated
with Bielschowsky silver staining. Rehydrated sections were
incubated in 20% AgNO3 solution for 15 min at 37°C, washed
with A.dest. and incubated in AgNO3 containing 25% NH4OH
(AgOH solution) for 10 min in the dark at 37°C. After washing
with 0.1% NH4OH solution, axons were visualized by adding
developer stock solution (5% formaldehyde, one drop of 65%
HNO3, 0,5g citric acid) to the AgOH solution for 4 min. Sections
were washed with 0.1% NH4OH and A.dest. and fixed in 5%
Na2S2O3 for 3 min followed by washing, dehydrating and
mounting. Spinal cord cross sections were analyzed by a
blinded observer using a BX-51 light microscope. Cellular
infiltrates were counted in three lesions within each spinal cord
segment (cervical, thoracic and lumbar) at 200x magnification
within the margin of a stereological grid and quantified per
square millimeter of white matter. Analysis of demyelinated
areas in the white matter was performed semi-automatically
with the help of CellP software. Axonal density was quantified in
silver impregnated sections by counting on a 100 µm
diameter grid.
Isolation of Splenic Cells
Spleens were removed on day 10 of EAE and disrupted with a
5 ml glass homogenizer. Cells were filtered through a 100 µM cell
strainer followed by erythrocyte lysis. Cells were washed with
cold DPBS and used for flow cytometry analysis or the MOG35-55
restimulation assay.
Isolation of CNS Infiltrating Cells
Spinal cord tissue was removed on day 21 of EAE after perfusion
with cold DPBS and disrupted with a 5 ml glass homogenizer.
Cells were transferred to a Percoll™ density gradient and
centrifuged at 800g for 20 min without break. Cells at the
interphases were collected, washed with cold DPBS and
analyzed by flow cytometry.
Isolation of Small Intestinal Lymphocytes
Single cell suspensions from lamina propria lymphocytes (LPL)
were obtained from the small intestine on day 3 of EAE using the
Lamina Propria Dissociation Kit (Miltenyi) following theFrontiers in Immunology | www.frontiersin.org 3manufacturer’s protocol. Isolated cells were purified with
Percoll™ density gradient centrifugation, washed with cold
DPBS and analyzed by flow cytometry.
In Vitro MOG35-55 Restimulation Assay
Splenocytes were isolated on day 10 of EAE and seeded at a
density of 3x106 cells/cm2 in Re-medium. MOG35-55 (20 µg/ml)
was added for stimulation and the cells were cultured 48 hours at
37°C. Supernatants were harvested and analyzed for secreted
cytokines by ELISA. To monitor proliferation, cells were labelled
with e450 proliferation dye (eBioscience) according to the
manufacturer’s protocol. Proliferation was assessed 72h later
by flow cytometry.
Treg Suppression Assays
CD4+CD25+ cells were isolated from the spleen on day 10 of
EAE using the CD4+CD25+ magnetic activated cell sorting
(MACS) isolat ion kit (Mi l tenyi) according to the
manufacturer’s instructions. CD4+CD25- cells from the same
donor mice were stained with the e450 proliferation dye
(eBioscience) according to the supplier’s protocol. Cells were
seeded at different ratios (no Tregs, 1:2, 1:4, 1:8 and 1:16) on an
anti-CD3 pre-coated (2 µg/ml, 145-2C11, BD Pharmingen) 96
well plate together with soluble anti-CD28 (2 µg/ml, 37.51, BD
Pharmingen). Suppression capacity was analyzed 72h later by
investigating proliferating CD4+CD25- cells via flow cytometry.
Flow Cytometry Analysis
Dead cells were excluded by a fixable viability dye eFluor®780
(0.2 ml/test, eBioscience). Nonspecific Fc-mediated interactions
were blocked by addition of 0.5 ml anti-CD16/32 (93,
eBioscience) for 10 min. For surface staining, cells were stained
with the respective fluorochrome conjugated antibodies for
30 min in PBS. For intracellular cytokine staining, cells were
stimulated for 4 h with ionomycin (1 µM) and PMA (50 ng/ml)
in the presence of monensin (2 mM). Cells were stained for
surface marker and made permeable by saponin buffer or Fix/
Perm (eBioscience) according to the manufacturer’s protocol.
Intracellular cytokines were stained with the respective
fluorochrome conjugated antibodies for 30-45 min. The
following antibodies were used: CD4 (RM4-5, eBioscience),
CD25 (PC61, BioLegend), FoxP3 (FJK-16s, eBiosciences), IL-
17A (eBio17B7, eBioscience), IL-10 (JESS-16E3, BioLegend),
IFN-g (XMG1.2, BD Biosciences).
Western Blot Analysis
Small intestinal LPL were isolated from control, LA and LA+PA
mice on day 3 of EAE. Splenic cells were isolated on day 10 of
EAE. Cells were treated with 1x Ripa lysis buffer [10xRipa: 150
mM NaCl, 38.5mM SDS, 50mM Tris, 134mM SDOX, 0.5 mM
EDTA, 1% NP40, complete protease inhibitor cocktail, Complete
Mini and phosphatase inhibitor cocktail, PhosStop (Roche
Diagnostic GmbH, Mannheim, Germany)] and centrifuged for
10 min at 10,000rpm. Protein concentration was determined
with the BC Assay Protein Quantitation Kit (Interchim). p38
protein was detected by using rabbit anti-p38 (Cell Signaling
Technology, 1:500). Phosphorylation of p38 protein was detectedJune 2021 | Volume 12 | Article 701626
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1:500). Mouse anti-b-actin (1:1000) was obtained from Millipore
(clone C4). C-6 glioma cells with or without anisomycin
treatment were used as pp38 positive or negative control (Cell
Signaling Technology). Goat anti-mouse Alexa Fluor 488
conjugated and goat anti-rabbit Alexa Fluor 647 conjugated
secondary antibodies (1:1000, Invitrogen) were used. Detection
was performed with the Fusion Capt Advance FX7.
Cytokine Measurement
Cytokine concentrations in cell culture supernatants were
analyzed by enzyme linked immunosorbent assay (ELISA) for
the secretion of IL-17A, IL-10 and IFN-g (ELISA DuoSet, R&D)
according to the manufacturer’s protocol.
In Vitro T Cell Differentiation Assay
Spleens from naïve C57Bl/6 mice were digested for 30 min in
RPMI media containing DNaseI (10 mg/ml) and Liberase TL
(1.67 Wünsch Units/ml). T cells were isolated by MACS using
the Pan T cell isolation kit (Miltenyi). Cells were fluorescently
stained with anti-CD4-FITC (RM4-5, eBioscience), anti-C25-
PECy5 (PC61.5, eBioscience), anti-CD44-PE (IM7, BioLegend)
and anti-CD62L-APC (MEL-14, eBioscience) to isolate naïve T
cells with a cell sorter. Naïve T cells were cultured on 96 well
plates together with plate-bound anti-CD3 (2 µg/ml, 145-2C11,
BD Pharmingen) and anti-CD28 (2 µg/ml, 37.51, BD
Pharmingen) and rhTGF-b1 (1 ng/ml) for Treg cell
differentiation. The cells were additionally treated with solvent
(PBS), LA (250µM) or LA+PA (PA 150µM) for 4 days and
analyzed for the frequency of CD25+FoxP3+ cells in CD4+
viable lymphocytes with flow cytometry. In some experiments,
cells were additionally treated with an IL-10 receptor blocker
(1µg/ml, Biolegend).
Human Study
The human study was approved by the ethics committee of the
Department of Medicine at the Ruhr-University Bochum
(registration number 15-5351, 4493-12, 17-6235). Prior to
study participation, all participants signed informed consent
forms. We performed an explorative subgroup analysis from a
previously published large cohort of PA-treated RRMS patients
(16) and analyzed the MS patients for body height and weight to
determine their age dependent body-mass index (BMI). A BMI ≥
30 defined MS patients as obese (https://www.cdc.gov/obesity/
adult/defining.html), non-obese MS patients had a BMI up to 30.
All MS patients were instructed to supplement 500 mg sodium-
propionate (PA) capsules twice daily for 90 days (Flexopharm,
Herne, Germany).
Flow Cytometry Analysis in Human Blood
Blood samples were analyzed before and after termination of PA
intake. Th17 cells were identified with aCD196 (CCR6)-PerCP
Cy5.5 (11A9; BD), aCD4-FITC (RPA-T4; BD), aCD161-PE
(DX-12; BD), aCD183 (CXCR3)-APC (1C6/CXCR3; BD) and
IL-17 (BD Bioscience) as previously described (16). For Treg
analysis, cells were stained with aCD4-FITC (RPA-T4,
eBioscience) , aCD25-APC (BC96, eBioscience) andFrontiers in Immunology | www.frontiersin.org 4intracellular aFoxP3-PE (236A/E7, eBioscience) by using
Foxp3/Transcription Factor Staining Buffer Set (eBioscience)
according to manufacturer protocol. Phenotyping was
performed on BD FACS Canto2 and analyzed by BD FACS
DIVA v6 software.
Quantification of PA in Feces
PA in fecal samples was analyzed as described previously (16, 19).
In brief, 10 mg of fecal samples were homogenized with HCl, ether
and crotonic acid as internal standard. The ether layer was mixed
with N-tert-butyldimethylsilyl-N-methyltrifluoroacetamide
(MTBSTFA), derivatized at room temperature for 24h and
analyzed by high-performance liquid chromatography-tandem
mass spectrometry (LC-MS/MS).
Statistical Analysis
Statistical analysis was performed using Graph Pad Prism. All
murine in vitro and ex vivo data were analyzed by one- or two-
way ANOVA followed by Tukey`s posttest. EAE data were
analyzed by Kruskal-Wallis test. Human data were analyzed by
two-tailed Mann-Whitney test. Data are presented as mean ±
SEM; *p<0.05, **p<0.01, or ***p<0.001 were considered to be
statistically significant.RESULTS
PA Rescues the LA-Diet Enhanced
Immunopathology in MOG35-55-EAE
by Increasing Treg Cell Frequencies
To investigate whether PA can revert the deleterious effects of
long-chain fatty acids during neuroinflammation, we fed mice a
standardized diet rich in the C12:0 fatty acid LA 4 weeks prior to
the induction of MOG35-55-EAE and treated mice either with
water (LA) or PA (LA+PA) starting from the day of
immunization. A control group was fed a matched control diet
and was treated with water from the day of immunization. All
mice had comparable body weights prior to EAE induction
independent of the diet (control: 20.8 ± 0.6 g versus LA: 21.4 ±
1.3 g, p=0.679). Clinical scoring revealed a more severe EAE
course in LA-diet mice compared to the control diet group and
treatment with PA in LA-diet fed mice resulted in an
amelioration of clinical signs (Figure 1A). The disease course
of LA-diet mice treated with PA was comparable to that of mice
receiving a control diet. Disease incidence (control: 10/11,
LA: 10/11, LA+PA: 11/12) and mortality were neither affected
by LA-diet feeding nor by PA treatment. The improved clinical
outcome in LA-diet mice treated with PA was reflected in the
histopathological analyses of the spinal cord on day 21 of EAE
(Figures 1B–F). LA-diet mice treated with PA showed a
significantly enhanced axonal density (Figure 1B), reduced
astrocyte numbers (Figure 1C) and reduced demyelination
(Figure 1D) compared to control-treated LA-diet mice.
Moreover, LA-diet feeding resulted in increased numbers of
infiltrating macrophages (Figure 1E) and T cells (Figure 1F)
compared to the controls, while treatment with PA in LA-diet fedJune 2021 | Volume 12 | Article 701626
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cord. Additional histological analyses revealed no effect on
Olig2+ cells and neurons (data not shown). We already
showed that LA induces Th17 cells during MOG-EAE while
PA increases Treg cell frequencies and their suppressive capacity
(8). Therefore, we additionally performed ex vivo flow cytometry
analysis of CD4+IL-17A+ Th17 and CD4+CD25+Foxp3+ Treg
cells in the spinal cord on day 21 of EAE. We observed increased
Th17 cell frequencies in LA-diet fed mice compared to control-
diet mice, whereas LA-diet fed mice treated with PA showed a
trend towards reduced Th17 frequencies nearly to the controlFrontiers in Immunology | www.frontiersin.org 5level (Figure 2A). In contrast, mice fed a LA-diet showed
decreased Treg frequencies, while PA treatment significantly
increased Treg cells, comparable to the Treg frequencies
observed in the control group (Figures 2B, C). These effects
were also observed in the spleen prior to the onset of EAE
symptoms. Ex vivo flow cytometry analysis on day 10 of EAE
revealed decreased Th17 cell frequencies in PA-treated LA-diet
mice compared to control-treated LA-diet mice (Figure 2D). In
contrast, PA treatment restored Treg cell frequencies in LA-diet
mice to a level observed in the control group (Figure 2E). We




FIGURE 1 | PA reverts the deleterious effect of a LA-rich diet in MOG-EAE. (A) Clinical course of MOG35-55-EAE. Mice were fed a LA-rich diet or control-diet 4
weeks prior to immunization and were additionally treated with PA (LA+PA, 150mM) or water (control; LA) by daily oral gavage starting from day 0. Data are shown
on a 10-point score scale as mean ± SEM and are pooled from two independent experiments (control n=11, LA n=11, LA+PA n=12). (B–F) Histological analysis of
spinal cord cross sections on day 21 of EAE. (B) Axonal density was analyzed by Bielschowsky silver staining. (C) Analysis of GFAP+ astrocytes. (D) Demyelination
was analyzed by LFB-PAS staining. (E) Infiltration of macrophages (Mac-3) and (F) CD3 positive T cells are reduced in LA-diet mice treated with PA compared to
control treated animals. Representative pictures are shown for each staining and group. Scale bars are 500 µm for LFB-PAS and 50 µm for Mac-3 and CD3. Arrows
indicate CD3+ cells, Mac3+ cells or demyelinated area. n=6 mice per group. *p<0.05 using Kruskal-Wallis test for (A), *p<0.05, **p<0.01, ***p<0.001 using one-way
ANOVA and Tukey’s posthoc test for (B–D). p.i., post immunization; LA, lauric-acid diet; PA, propionic acid.June 2021 | Volume 12 | Article 701626
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of the small intestine on day 3 of EAE showed a decrease of Th17
cell frequencies in LA-diet mice compared to the controls
independent of PA treatment (Figure 2F). However, PA
treatment in LA-diet mice increased Treg cell frequencies in
the gut, thus inhibiting the LA-diet induced decrease of Treg cells
compared to controls (Figure 2G). In contrast, Th1 cells were
not altered in the spinal cord, the spleen or the gut by LA-diet
feeding and PA treatment (data not shown). Our data thus
indicate that PA treatment rescued the disease enhancing
effects of a LA-diet by inhibiting Th17 cell expansion and
increasing Treg cell frequencies.
PA Reverts the Deleterious Effect of a LA-
Rich Diet by Increased IL-10 Production
and Enhanced Suppression Capacity of
Treg Cells
We next investigated the potential mechanism of PA to reduce
th e LA-d i e t enhanced immunopa tho l ogy du r ing
neuroinflammation. Ex vivo analysis of the spleen in a recall
assay with MOG35-55 revealed an increased proliferation of
CD4+ T cells in splenocytes from LA-diet mice compared to
the control group (Figures 3A, B). Yet, PA-treatment during
LA-diet feeding blunted the enhanced proliferation of CD4+ T
cells and reduced proliferating T cell frequencies to levels
observed in the control-diet group. Moreover, ex vivo recall
assays revealed a significantly enhanced IL-17A secretion in
splenocytes isolated from LA-diet mice compared to the
controls, which was decreased by PA treatment during LA-dietFrontiers in Immunology | www.frontiersin.org 6feeding (Figure 3C). Interestingly, we observed a significant
increase of the anti-inflammatory cytokine IL-10 in cells
derived from LA-diet mice treated with PA compared to the
control-treated LA-diet group and mice receiving a control diet
(Figure 3D). Since IL-10 acts as a suppressor cytokine of
enhanced pro-inflammatory immune cell responses, we next
investigated the suppressive capacity of Treg cells isolated from
control mice, control-treated LA-diet mice and LA-diet mice
treated with PA (Figures 3E, F). The suppression of CD4+
effector T cells was significantly reduced by Treg cells isolated
from LA-diet fed mice (Figure 3E, black squares). In contrast,
PA treatment during LA-diet feeding normalized the suppressive
capacity of Treg cells (Figure 3E, grey triangle) to a level
observed in the control group (Figure 3E, white dots). We
next performed in vitro T cell differentiation assays to assess
the potential link of PA treatment and IL-10 secretion in Treg
cells. The addition of PA to T cell cultures treated with LA
normalized Treg cell frequencies to comparable levels observed
in controls (Figure 3G). Moreover, PA treatment significantly
increased the frequencies of IL-10 producing Treg cells as
detected by flow cytometry (Figure 3H) and ELISA
(Figure 3I). We next blocked the IL-10 signaling pathway
during Treg differentiation by adding an IL-10 receptor blocker
(IL-10R Block, 1µg/ml). This blockade inhibited the effect of PA
on Treg cell differentiation, as we observed similar FoxP3+ Treg
cells (Figure 3J) and IL-10 producing Treg cells (Figure 3K) in
all investigated groups. Our data thus indicate that PA enhances
the IL-10 secretion in Treg cells, thereby boosting the suppressive
capacity of Treg cells. We further investigated the potentialA B C
D E F G
FIGURE 2 | PA treatment reverts the pro-inflammatory effect of a LA-rich diet and increases Treg cell frequencies during MOG-EAE. Mice were fed a LA-rich diet or
control-diet 4 weeks prior to immunization and were additionally treated with PA (LA+PA) or water (control; LA) by daily oral gavage starting from day 0. (A–C) Ex
vivo flow cytometry analysis of (A) CD4+IL-17+ Th17 cells and (B) CD25+FoxP3+ Treg cells in the spinal cord on day 21 of EAE (n=6 per group). (C) Representative
flow cytometry images of CD25+FoxP3+ Treg cells in the spinal cord on day 21 of EAE. (D, E) Ex vivo flow cytometry analysis of (D) CD4+IL-17+ Th17 cells and
(E) CD25+FoxP3+ Treg cells in the spleen on day 10 of EAE (n=5 per group). (F, G) Ex vivo flow cytometry analysis of (F) CD4+IL-17+ Th17 cells and (G)
CD25+FoxP3+ Treg cells in the small intestine on day 3 of EAE (n=8 per group). *p<0.05, **p<0.01, ***p<0.001 using one-way ANOVA and Tukey’s posthoc test.June 2021 | Volume 12 | Article 701626
Haase et al. Rescue of HFD-Enhanced Autoimmunityinvolvement of the mitogen-activated protein kinase (MAPK)
signaling pathway p38 as relevant contributor to enhanced Th17
induction by LA (8). At the post-transcriptional level, PA
treatment in LA-diet fed mice inhibited the increase of p38
phosphorylation as observed in control-treated LA-diet mice
(Figure 4). This effect was even more pronounced in the small
intestine on day 3 of EAE (Figure 4A) compared to the spleen
analyzed prior to the onset of EAE symptoms (day 10 p.i.,
Figure 4B). These data indicate that PA reverts the deleteriousFrontiers in Immunology | www.frontiersin.org 7effect of a LA-rich diet by decreasing the LA-induced
phosphorylation of p38-MAPK.
PA Supplementation in Obese MS Patients
Can Restore the Imbalanced Th17-
Treg Homeostasis
We translated our findings to human disease and performed an
explorative study in a small cohort of MS patients (disease
characteristics are summarized in Table 1). We included MSA B
E F
C D
G H I KJ
FIGURE 3 | PA reverts the deleterious effect of a LA-rich diet by increased IL-10 production and enhanced suppression capacity of Treg cells. Mice were fed a LA-
rich diet or control-diet 4 weeks prior to immunization and were additionally treated with PA (LA+PA) or water (control; LA) by daily oral gavage starting from day 0.
(A, B) Ex vivo proliferation assay of CD4+ T cells isolated from the spleen on day 10 of EAE. Isolated cells were re-stimulated with MOG35-55 in vitro and proliferation
was assessed by flow cytometry 72h later. (A) Quantification of proliferating cells from control, LA or LA+PA treated mice (n=6 per group). (B) Representative
histograms of proliferating CD4+ T cells. (C, D) Splenic cells were isolated on day 10 of EAE and re-stimulated with MOG35-55 in vitro for 48h. Quantification of
(C) IL-17A and (D) IL-10 in cell culture supernatants analyzed by ELISA (n=6 per group). (E, F) Treg suppression assay of ex vivo obtained CD4+CD25+ splenic T
cells isolated from control, LA or LA+PA treated mice on day 10 of EAE. CD4+CD25+ T cells were co-cultured with e450 labeled CD4+CD25- cells for 72h (n=5 per
group). (F) Representative histograms of proliferating CD4+ cells co-cultured with or without Treg cells analyzed by flow cytometry. (G–I) Splenic naïve CD4+ T cells
were treated with PBS (control), LA (250µM) or LA+PA (PA 150µM) under Treg polarizing conditions. Flow cytometry analysis of CD25+FoxP3+ cells (G) and
IL10+FoxP3+ cells (H) in viable CD4+ cells was performed 96h later (n=6 from 2 independent experiments). (I) Quantification of IL-10 in cell culture supernatants of
Treg differentiation assays analyzed by ELISA. (J, K) IL-10 signaling was blocked by the addition of an IL-10 receptor blocker (1µg/ml) to CD4+ T cell differentiation
assay under Treg polarizing conditions (n=6 from two independent experiments). Flow cytometry analysis of CD25+FoxP3+ cells (J) and IL10+FoxP3+ cells (K) in
viable CD4+ cells was performed 96h later (n=6 from 2 independent experiments). ns, not significant. *p<0.05, **p<0.01, ***p<0.001 using one-way ANOVA and
Tukey’s posthoc test.June 2021 | Volume 12 | Article 701626
Haase et al. Rescue of HFD-Enhanced Autoimmunitypatients with a body mass index (BMI) higher than 30 (obese MS
patients) compared to MS patients with a BMI below 30 (non-
obese). We first investigated fecal PA concentrations in both
groups to prove whether obesity might further affect the altered
gut microbiota metabolomics of MS patients as observed
previously (16). Compared to non-obese MS patients, fecal PA
concentrations were significantly reduced in obese MS patients
(Figure 5A). We next hypothesized that reduced PA
concentrations in the gut may coincide with altered immune
cell frequencies in obese MS patients that may be restored by PA
supplementation as observed in our murine data. To investigateFrontiers in Immunology | www.frontiersin.org)
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this, we analyzed Th17 and Treg cell frequencies in the blood at
baseline and after 90 days of PA supplementation as add-on
therapy to the pre-existing immunomodulatory therapy. At
baseline, obese MS patients displayed reduced Treg frequencies
(Figure 5B) but increased Th17 frequencies (Figure 5C)
compared to the non-obese group, indicating an obesity-
related imbalance of Th17 and Treg cells. Importantly, PA
supplementation increased Treg frequencies in both MS-
groups, albeit only statistically significant in non-obese MS
patients (Figure 5B). Moreover, Th17 cell frequencies were
significantly decreased in obese MS patients after PA intake,
and showed a trend towards lower cell counts in non-obese MS
patients supplemented with PA compared to the baseline
(Figure 5C). Our data thus indicate that PA supplementation
in MS patients is able to restore the obesity-associated imbalance
of Th17-Treg homeostasis, probably involving an alteration of
fecal PA concentrations.DISCUSSION
Our data add to the recently identified property of LCFA to
exacerbate EAE by shifting the T cell pool towards pro-
inflammatory Th17 cells (8). We observed a LCFA-induced
increase of Th17 cells in the spinal cord as target organ during
EAE, as well as increased Th17 frequencies in the spleen and theTABLE 1 | MS patient characteristics.
Characteristics MS BMI<30 MS BMI>30
(n=34) (n=6)
Female sex, n (%) 19 (55.8%) 3 (50%)
Age, years, mean ± SD 55,70 ( ± 10.54) 56,14 ( ± 11.63
Subgroups
RRMS 9 (26.5%) 2 (33.3%)
SPMS 20 (58.8%) 2 (33.3%)
PPMS 5 (14.7%) 2 (33.3%)
Therapy regimen
Interferon B 2 0
Dimethylfumarate 7 2
Fingolimod 1 0
Steroids ithc. 26 5A B
C D
FIGURE 4 | PA decreases the LA-induced phosphorylation of p38-MAPK in the spleen and the small intestine. Mice were fed a LA-rich diet or control-diet 4 weeks
prior to immunization and were additionally treated with PA (LA+PA) or water (control; LA) by daily oral gavage starting from day 0. (A, B) Western Blot analysis of
p38 and phosphorylated p38 (pp38) from small intestinal LPL isolated on day 3 of EAE. (A) Quantification of p38 expression (black) and pp38 (white) in control, LA
and LA+PA treated mice normalized to b-Actin expression. (B) Representative Western Blot images. (C, D) Western Blot analysis of p38 and pp38 from splenocytes
isolated in day 10 of EAE. (C) Quantification of p38 expression (black) and pp38 (white) in control, LA and LA+PA treated mice normalized to b-Actin expression.
(D) Representative Western Blot images. *p<0.05 using one-way ANOVA and Tukey’s posthoc test.June 2021 | Volume 12 | Article 701626
Haase et al. Rescue of HFD-Enhanced Autoimmunitygut prior to the onset of EAE symptoms. More importantly, we
describe the potential of dietary SCFA supplementation to
counteract this disease enhancing effect by inducing functionally
competent Treg cells that prevent the Th17-mediated exacerbation
via increased IL-10 secretion. We translated these findings to a
small cohort of MS patients and identified an imbalanced Th17-
Treg homeostasis in obese patients paralleled by reduced PA
concentrations in the gut. Interestingly, PA supplementation
could restore the Th17/Treg balance in MS patients,
demonstrating the relevance of our findings for human diseases
involving a T cell-centered immunopathology.
PA treatment in mice fed a LCFA-diet restored Treg cell
frequencies in the spinal cord, together with the prevention of
LA-induced EAE severity. This Treg cell induction was initiated
in the small intestine prior to the onset of EAE symptoms,
identifying the gut as a prominent compartment mediating the
preventive effect of PA treatment on LCFA-enhanced
immunopathology in neuroinflammation. Indeed, the gut is
the primary absorption interface for nutrients and an
important tolerogenic environment shaping our immune
system (20–22). Moreover, the gut commensal bacteria are
highly important contributors to EAE pathology (23, 24)
and different bacterial species are implied in either Th17 or
Treg cell development (25–27). Vice versa, IL-17 secreting Th17
cells were recently shown to modulate the intestinal microbiota,
thereby indirectly affecting CNS autoimmunity (28). Albeit these
data firstly question the encephalitogenicity of IL-17 during
EAE, they support the importance of the gut and the gut
microbiota as relevant Th17-affecting compartment during
neuroinflammation. Moreover, the gut microbiota composition
is mainly affected by antibiotic intake (29) and dietary habits
(30), and we recently observed that diets rich in LCFA alter the
gut microbiota composition towards a Th17 cell inducing
environment (8). LCFA intake decreases SCFA concentrationsFrontiers in Immunology | www.frontiersin.org 9in the gut, probably reducing Treg cell functionality during EAE
(8). The here presented beneficial effect of PA treatment on the
high-fat diet-enhanced immunopathology may therefore be
linked to (i) a prevention of the LCFA-induced alteration of
the gut microbiota composition towards Th17 inducing
microorganisms, (ii) restoration of microbial species inducing
an anti-inflammatory environment, or (iii) a short-term increase
of mucosal PA concentrations with direct consequences on Treg
cells. Particularly the first two points need to be proven in future
studies, investigating the gut microbiota composition in LCFA-
diet fed mice treated with PA or vehicle.
PA treatment during LCFA-intake could restore the suppressive
capacity of Treg cells during EAE, correlating with enhanced IL-10
secretion as detected in an antigen-specific re-stimulation assay and
in in vitro Treg cultures. Of note, IL-10 signaling in Treg cells is
required for the suppression of Th17 cell-mediated inflammation
(31), strengthening our concept that PA rescues the LCFA
enhanced immunopathology by increasing the IL-10 mediated
suppressive capacity of Treg cells. Yet, we cannot necessarily
exclude that other mechanisms besides IL-10 secretion might be
responsible for the increased Treg suppressive capacity in vivo. As
such, suppression by modulation of dendritic cell maturation or
metabolic disruption may be of potential importance (32, 33).
However, Treg cell-derived IL-10 seems to be required for the
control of inflammatory events at mucosal interfaces including the
lungs and the colon (34), supporting our hypothesis that PA
prevents a Th17-mediated immunopathology involving the gut.
While other studies identified a potential involvement of STAT3
phosphorylation in IL-10 mediated suppression of Treg cells (35),
we propose the involvement of the p38 MAPK signaling pathway, a
well-known integrator of environmental stress that has previously
been shown to be involved in T cell differentiation (36) and to be
critical in models of MS (37). Our data confirm previous studies,
demonstrating that LA treatment increases p38 phosphorylation inA B C
FIGURE 5 | PA supplementation in obese MS patients can restore the imbalanced Th17-Treg homeostasis. (A) PA concentrations were analyzed in fecal samples of
non-obese (BMI <30; n=16) and obese (BMI >30; n=4) MS patients by LC-MS/MS. (B, C) Flow cytometry analysis of (B) Treg and (C) Th17 cells in the blood of non-
obese (BMI <30) and obese (BMI >30) MS patients at baseline and after 90 days of PA intake (1000mg per day). BMI <30: baseline n=34, d90 n=22. BMI >30: baseline
n=6, d90 n=5. p values are indicated in the figure and were determined by Mann-Whitney test. ns, not significant. *p<0.05, **p<0.01 using Mann-Whitney test.June 2021 | Volume 12 | Article 701626
Haase et al. Rescue of HFD-Enhanced AutoimmunityTh17 cells, whereas Treg cell differentiation correlated with
decreased p38-MAPK activation (8).
The here presented data are not only relevant for EAE as a
prototypemodel of T cell-mediated neuroinflammation, but also for
other diseases involving an imbalance in Th17-Treg homeostasis.
Moreover, LCFA such as LA are a major component of our modern
‘Western diet’. Hence, our data may be of potential importance
when investigating dietary induced obesity. This hypothesis is
strengthened by our explorative study with a small group of PA-
treated MS patients, demonstrating that obesity in T cell mediated
neuroinflammation affects the fecal metabolite composition and
shifts the T cell balance towards increased pro-inflammatory T cells.
The observed reduction of fecal PA concentrations in obese MS
patients compared with non-obese patients might be related to an
altered microbiota composition and functionality as recently
indicated (38). However, analysis of the gut microbiome
composition and larger sample sizes will be necessary to prove
this concept. Yet, our data add to the observation that obesity
correlates with an imbalance in peripheral Th17-Treg homeostasis
(39). We observed altered Treg and Th17 cell numbers in MS
patients with a BMI higher than 30 compared to normal-weight
patients. Until now, only in vitro studies identified a potential
benefit of PA on obesity-associated inflammation (40, 41). To our
knowledge, this is the first study demonstrating that PA
supplementation may counteract obesity-enhanced pro-
inflammatory immune responses in neuroinflammatory diseases,
further attracting its therapeutic potential. Yet, we performed an
explorative study in a small number of obese MS patients and larger
cohorts will be necessary in the future to confirm the therapeutic
potential of PA treatment in obese patients. Moreover, we solely
analyzed immune cell frequencies in the blood rather than
investigating a direct link of PA intake and the clinical outcome
of obese MS patients. However, we could recently demonstrate that
PA supplementation to MS patients beneficially affected the annual
relapse rates and disease stability due to increased Treg cells (16),
indicating that the observed restoration of Treg cells in obese MS
patients may also improve their clinical outcome. It is long accepted
that obesity correlates with metabolic alterations and systemic
inflammation, contributing to severe comorbidities such as type 2
diabetes, cardiovascular diseases, asthma and certain types of cancer
(42–45). Therefore, the here identified benefit of PA
supplementation in obese people may also prevent obesity
associated comorbidities, making its therapeutic potential even
more attractive.Frontiers in Immunology | www.frontiersin.org 10DATA AVAILABILITY STATEMENT
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